Description: Greenbrook TMS Inc., together with its subsidiaries, controls and operates a network of outpatient mental health services centers in the United States. Its centers specialize in the provision of transcranial magnetic stimulation (TMS) therapy, an FDA-cleared neurostimulation therapy for the treatment of major depressive disorder and other mental health disorders. The company also offers Spravato, an esketamine nasal spray; and other treatment modalities for the treatment of depression and related psychiatric services. Greenbrook TMS Inc. was founded in 2011 and is headquartered in Toronto, Canada. As of December 9, 2024, Greenbrook TMS Inc. operates as a subsidiary of Neuronetics, Inc.
Home Page: www.greenbrooktms.com
890 Yonge Street
Toronto,
ON
M4W 3P4
Canada
Phone:
416 322 9700
Officers
| Name | Title |
|---|---|
| Mr. William P. Leonard | President, CEO & Director |
| Mr. Peter Willett | Chief Financial Officer |
| Dr. Geoffrey Garland Grammer M.D. | Chief Medical Officer |
| Mr. Andrew Crish | Chief Operating Officer |
| Glen Akselrod | Investor Relations Officer |
| Ms. Iris Krug | VP of Compliance & Privacy Officer |
| Ms. Brittany Schwemmer | Vice President of Human Resources |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 489 |